

This update includes 7927 reports of 18481 suspected Adverse Events Following Immunisation (AEFI) associated with administration of **5 A/H1N1 vaccines** (Celvapan, Fluval P, Focetria, Pandemrix and Panvax) received by UMC up to February 5, 2010 from National Centres for pharmacovigilance of **11 countries** (Estonia, Finland, Germany, Greece, Hungary, Iceland, Italy, Netherlands, Norway, Singapore and the United Kingdom).

- This update contains listings of suspected AEFI (MedDRA terminology) per vaccine
- The frequency of an AEFI can not be calculated accurately from passive reporting systems, only the reporting frequency.
- This update can contain reports of suspected 'vaccine failure'; these reports cannot be used to assess vaccine efficacy/effectiveness
- The number of reports shown for the different vaccines cannot be used to compare the safety or the benefit-risk balance of these vaccines because of differences in the numbers of people receiving each vaccine
- Some NCPs report overviews of the AEFI that were reported in relation to A/H1N1 vaccines on their own websites. These are listed on UMC's A/H1N1 Flu Vaccine Monitoring webpage (<http://www.who-umc.org/DynPage.aspx?id=85898> ). The numbers on these websites may differ from those in this overview due to the timing of sending reports to UMC.
- The Committee for Medicinal Products for Human Use (CHMP) has recommended to specifically report on 'Adverse events of special interest': neuritis, convulsions, anaphylaxis, encephalitis, vasculitis, Guillain-Barré syndrome, Bell's palsy, demyelinating disorders, laboratory-confirmed vaccination failure. These are listed in a separate table.

#### **General information about the Uppsala Monitoring Centre and adverse reaction data**

*The Uppsala Monitoring Centre (the UMC) is the field-name of the WHO Collaborating Centre for International Drug Monitoring. The UMC is responsible for the management of the WHO Programme for International Drug Monitoring. The WHO Programme for International Drug Monitoring provides a forum for WHO member states to collaborate in the monitoring of drug safety. Within the Programme, individual case reports of suspected adverse drug reactions are collected and stored in the WHO Global Individual Case Safety Report database, called VigiBase, presently containing over 4.9 million case reports. In each of the countries participating in the Programme, the government has designated a National Centre for Pharmacovigilance (NC). All individual case reports in VigiBase are sent to UMC by NCs on a continuous basis but with different frequencies.*

- *An individual case report of suspected adverse drug reactions contained in VigiBase does not necessarily imply that the adverse event is associated with the vaccine (causality). Reports about adverse reactions are accepted in the database even if it is only suspected that there might be an association between the vaccine and the adverse reaction. Therefore, the information in the database may include true adverse reactions of a vaccine as well as coincidental events e.g. due to a disease in the patient or another medicine which the patient is taking at the same time.*
- *An adverse reaction is considered to be serious if it results in the patient's death, is life-threatening, death, requires (prolongation of) hospitalisation, results in significant disability/incapacity, or (for drugs other than vaccines) if the patient is unable to work or go to school.*
- *A single adverse reaction report may contain more than one adverse event. Therefore, the number of registered adverse events is usually higher than the number of adverse reaction reports.*
- *NCs receive the reports from healthcare professionals, patients and manufacturers in their country.*
- *Causality assessment and investigation of individual reports is performed by NCs*

*Both healthcare professionals and patients are encouraged to continue reporting adverse reactions to their NCs.*

## Celvapan

UMC's database contains 3 reports of 9 suspected AEFI associated with administration of Celvapan reported by 1 country. The gender distribution is males: 2; females 1.

Serious reports <sup>a</sup>	2
fatal outcomes	0

<sup>a</sup> death, is life-threatening, requires (prolongation of) hospitalisation, results in significant disability/incapacity

<b>System Organ Class</b> (most frequently reported events)	<b>nr events</b>
General disorders and administration site conditions (pyrexia, chills)	2
Immune system disorders (Anaphylactic reaction)	1
Infections and infestations (rhinitis)	1
Injury, poisoning and procedural complications (vaccination failure)	1
Nervous system disorders (dizziness)	1
Respiratory, thoracic and mediastinal disorders (cough)	1
Skin and subcutaneous tissue disorders (hyperhydrosis)	1
Vascular disorders (hot flush)	1

<b>Adverse Events of Special Interest</b>	<b>nr events</b>
Anaphylaxis	1
Laboratory-confirmed vaccination failure	1

<b>Age group</b>	<b>nr reports</b>
28 days to 23 months	2
18 to 44 years	1

**Fluval P**

UMC's database contains 5 reports of 20 suspected AEFI associated with administration of Focetria reported by 1 country. The gender distribution is males: 2; females 3.

Serious reports <sup>a</sup>	4
fatal outcomes	1

<sup>a</sup> death, is life-threatening, requires (prolongation of) hospitalisation, results in significant disability/incapacity

<b>System Organ Class</b> (most frequently reported events)	<b>nr events</b>
Cardiac disorders (cardiac failure)	1
Gastrointestinal disorders (vomiting, nausea, hypoaesthesia oral)	3
General disorders and administration site conditions (asthenia, death, local swelling, malaise, pyrexia)	5
Immune system disorders (anaphylactoid reaction)	1
Infections and infestations (bronchitis)	1
Injury, poisoning and procedural complications (fall)	1
Nervous system disorders (dizziness, hypotonic-hyporesponsive episode)	2
Skin and subcutaneous tissue disorders (pruritus, rash, urticaria, allergic dermatitis)	5
Vascular disorders (pallor)	1

<b>Adverse Events of Special Interest</b>	<b>nr events</b>
Anaphylaxis	2

<b>Age group</b>	<b>nr reports</b>
2 to 11 years	1
18 to 44 years	1
45 to 64 years	2
65 to 74 years	1

## Focetria

UMC's database contains 2727 reports of 6110 suspected AEFI associated with administration of Focetria reported by 3 countries. The gender distribution is males: 787; females 1936; not reported: 4.

Serious reports <sup>a</sup>	132
fatal outcomes	11

<sup>a</sup> death, is life-threatening, requires (prolongation of) hospitalisation, results in significant disability/incapacity

<b>System Organ Class</b> (most frequently reported events)	<b>nr events</b>
Blood and lymphatic system disorders (lymphadenopathy, thrombocytopenia)	60
Cardiac disorders (palpitations, tachycardia, atrial fibrillation, acute coronary syndrome)	84
Ear and labyrinth disorders (vertigo, tinnitus, ear pain)	89
Endocrine disorders (thyroid disorder)	2
Eye disorders (visual impairment, eye swelling, eye irritation, conjunctivitis, eye pain)	75
Gastrointestinal disorders (nausea, diarrhoea, vomiting, abdominal pain)	771
General disorders and administration site conditions (pyrexia, fatigue, injection site pain, influenza like illness, malaise)	1892
Hepatobiliary disorders (hepatitis)	1
Immune system disorders (hypersensitivity, anaphylactic reaction, anaphylactic shock)	21
Infections and infestations (rhinitis, nasopharyngitis, pharyngitis, influenza)	142
Injury, poisoning and procedural complication (contusion)	14
Investigations	64
Metabolism and nutrition disorders (decreased appetite, hyperglycaemia)	34
Musculoskeletal and connective tissue disorders (myalgia, pain in extremity, arthralgia, musculoskeletal stiffness)	704
Nervous system disorders (headache, dizziness, dysgeusia, paraesthesia)	1115
Pregnancy, puerperium and perinatal conditions (intra-uterine death, abortion spontaneous, complication of pregnancy)	17
Psychiatric disorders (listless, insomnia, nightmare, restlessness, tearfulness)	91
Renal and urinary disorders (dysuria)	7
Reproductive system and breast disorders (breast pain, galactorrhoea, lactation disorder, suppressed lactation)	16
Respiratory, thoracic and mediastinal disorders (cough, dyspnoea, oropharyngeal pain, asthma, bronchospasm)	424
Skin and subcutaneous tissue disorders (rash, pruritus, erythema, urticaria, hyperhidrosis, dermatitis allergic)	426
Vascular disorders (pallor, flushing, haematoma, hypotension, peripheral coldness)	61

<b>Adverse Events of Special Interest</b>	<b>nr events</b>
Anaphylaxis	105
Bells palsy	4
Convulsions	22
Demyelination	13
Encephalitis	4
Guillain-Barré syndrome	9
Neuritis	3
Vasculitis	3

<b>Age group</b>	<b>nr reports</b>
Not specified	124
28 days to 23 months	52
2 to 11 years	189
12 to 17 years	55
18 to 44 years	1039
45 to 64 years	913
65 to 74 years	251
75 > years	104

## Pandemrix

UMC's database contains 5132 reports of 12167 suspected AEFI associated with administration of Pandemrix reported by 6 countries. The gender distribution is males: 2349; females 2725; not reported: 58.

Serious reports <sup>a</sup>	232
fatal outcomes	22

<sup>a</sup> death, is life-threatening, requires (prolongation of) hospitalisation, results in significant disability/incapacity

<b>System Organ Class</b> (most frequently reported events)	<b>nr events</b>
Blood and lymphatic system disorders (lymphadenopathy, lymphadenitis)	44
Cardiac disorders (tachycardia, palpitations, cyanosis)	64
Ear and labyrinth disorders (ear pain, vertigo, hearing impaired, tinnitus)	41
Eye disorders (eye swelling, ocular hyperaemia, lacrimation increased, visual impairment, conjunctivitis, photophobia)	105
Gastrointestinal disorders (vomiting, diarrhoea, nausea, abdominal pain)	1490
General disorders and administration site conditions (pyrexia, hyperpyrexia, injection site pain, fatigue, influenza like illness, malaise)	5944
Hepatobiliary disorders (jaundice)	1
Immune system disorders (hypersensitivity, anaphylactic reaction, anaphylactic shock)	36
Infections and infestations (rhinitis, nasopharyngitis, pneumonia, ear infection)	212
Injury, poisoning and procedural complication (contusion, drug exposure during pregnancy)	16
Investigations (body temperature increased, body temperature decreased, heart rate increased)	59
Metabolism and nutrition disorders (decreased appetite, oligodipsia, polydipsia)	249
Musculoskeletal and connective tissue disorders (myalgia, pain in extremity, arthralgia, musculoskeletal stiffness, musculoskeletal weakness)	638
Neoplasms benign, malignant and unspecified (lymphangioma)	1
Nervous system disorders (headache, dizziness, somnolence, crying, febrile convulsion, paraesthesia)	1416
Pregnancy, puerperium and perinatal conditions (abortion spontaneous, intra-uterine death, premature baby, premature labour, stillbirth)	20
Psychiatric disorders (listless, tearfulness, insomnia, sleep disorder, restlessness)	434
Renal and urinary disorders (enuresis, incontinence, micturition urgency, oliguria, polyuria)	6
Reproductive system and breast disorders (vaginal haemorrhage, suppressed lactation, lactation disorder)	17
Respiratory, thoracic and mediastinal disorders (cough, dyspnoea, oropharyngeal pain, tachypnoea, asthma, bronchospasm)	538
Skin and subcutaneous tissue disorders (rash, erythema, pruritus, urticaria, hyperhidrosis,)	679
Vascular disorders (pallor, hypotension, peripheral coldness, flushing, hypertension)	157

<b>Adverse Events of Special Interest</b>	<b>nr events</b>
Anaphylaxis	152
Bells palsy	1
Convulsions	95
Demyelisation	1
Guillain-Barré syndrome	1
Neuritis	2
Vasculitis	3

<b>Age group</b>	<b>nr reports</b>
Not specified	7
28 days to 23 months	1553
2 to 11 years	2347
12 to 17 years	35
18 to 44 years	956
45 to 64 years	193
65 to 74 years	19
75 > years	22

## Panvax

UMC's database contains 61 reports of 176 suspected AEFI associated with administration of Panvax reported by 1 country. The gender distribution is males: 17; females 44.

Serious reports <sup>a</sup>	0
fatal outcomes	0

<sup>a</sup> death, is life-threatening, requires (prolongation of) hospitalisation, results in significant disability/incapacity

<b>System Organ Class (most frequent)</b>	<b>nr events</b>
Blood and lymphatic system disorders (lymphadenopathy)	1
Ear and labyrinth disorders (vertigo)	2
Eye disorders (eye pain, scleritis)	2
Gastrointestinal disorders (diarrhoea, vomiting, nausea)	12
General disorders and administration site conditions (pyrexia, pain, chills)	32
Immune system disorders (hypersensitivity, anaphylactic reaction)	2
Infections and infestations (influenza, upper respiratory tract infection, rhinitis)	16
Metabolism and nutrition disorders (dehydration)	1
Musculoskeletal and connective tissue disorders (myalgia, musculoskeletal pain, arthralgia)	12
Nervous system disorders (headache, dizziness, lethargy, hypoaesthesia, paraesthesia)	26
Psychiatric disorders (confusional state, disorientation)	2
Respiratory, thoracic and mediastinal disorders (cough, dyspnoea, oropharyngeal pain, tachypnoea, asthma, bronchospasm)	27
Skin and subcutaneous tissue disorders (rash, pruritus, urticaria, periorbital oedema)	40
Vascular disorders (flushing)	1

<b>Adverse Events of Special Interest (AESI)</b>	<b>nr REPORTS</b>
Anaphylaxis	15
Vasculitis	1

<b>Age group</b>	<b>nr reports</b>
Not specified	1
18 to 44 years	34
45 to 64 years	25
65 to 74 years	1